文献速递妇科

FAP阳性癌症相关成纤维细胞高丰度预测CD8 T细胞高密度的高级别浆液性卵巢癌患者预后不良

High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
PubMed 文献 · Gynecol Oncol · 2025-02-05

本研究探讨高级别浆液性卵巢癌(HGSC)肿瘤微环境中FAP阳性成纤维细胞与CD8+淋巴细胞浸润的临床相关性。在发现队列(N=113)和验证队列(N=121)中,高CD8+细胞密度肿瘤中FAP高表达与更短的无进展生存期(11.4 vs 18.6个月,HR 4.03)和总生存期(31.5 vs 76.9个月,HR 2.83)相关。结论认为FAP阳性成纤维细胞浸润与高CD8+细胞密度HGSC的不良预后相关,靶向FAP+成纤维细胞亚群可能增强T细胞的积极预后效应。

要点

  • HGSC肿瘤微环境中高CD8+细胞浸润与更长总生存期相关,与既往认识一致。
  • CD8+细胞高密度肿瘤中FAP高表达与更短中位无进展生存期相关(11.4 vs 18.6个月,HR 4.03)。
  • 验证队列中CD8+细胞高密度病例FAP高强度与更短总生存期相关(31.5 vs 76.9个月,HR 2.83)。

核心结论

  • FAP阳性成纤维细胞浸润与高CD8+细胞密度HGSC的不良预后相关,靶向FAP+成纤维细胞亚群可能增强T细胞的积极预后效应。

研究设计与样本

  • 发现队列(N=113)HGSC中采用免疫组化分析肿瘤微环境FAP与CD8表达,结果与总生存期和无进展生存期相关分析。
  • 在独立验证队列(N=121)HGSC及公共可用数据集中验证发现。

主要发现

  • HGSC肿瘤微环境中高CD8+细胞浸润与更长总生存期相关。
  • CD8+细胞高密度肿瘤中FAP表达增高与更短中位无进展生存期相关(11.4 vs 18.6个月,HR 4.03,95%CI 1.38-11.72,p=0.01)。
  • 验证队列中CD8+细胞高密度病例FAP高强度与更短总生存期相关(31.5 vs 76.9个月,HR 2.83,95%CI 1.17-6.86,p=0.02)。
  • 多因素分析结果一致,公共数据集亦证实高FAP表达与高CD8+细胞密度HGSC不良预后相关。

临床怎么用

  • 作者认为靶向FAP+成纤维细胞亚群可能解锁肿瘤微环境局部免疫激活,从而增强卵巢癌中T细胞的积极预后效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Studies have implied that fibroblasts may act as regulators of immune cells in the tumor microenvironment (TME). We investigated the clinical relevance of fibroblast activation protein (FAP) positive stroma in high-grade serous ovarian cancer (HGSC) in relation to CD8+ lymphocyte's infiltration. METHODS: In a discovery cohort (N = 113) of HGSC, expression of FAP and CD8 in the TME was analyzed with immunohistochemistry. Results were correlated with overall survival (OS) and progression-free survival (PFS). The findings were validated in an independent cohort of HGSC (N = 121) and in public available datasets. RESULTS: High infiltration of CD8+ cells in the TME of HGSC was found to be associated with longer OS, as previously known. Increased expression of FAP was associated with shorter median PFS (11.4 vs. 18.6 months) in tumors with high density of CD8+ cells (HR 4.03, CI 95 % 1.38-11.72, p = 0.01). Similarly, in the validation cohort, high intensity of FAP in cases with high density of CD8+ cells was associated with shorter OS, 31.5 vs 76.9 months (HR 2.83; 95 % CI 1.17-6.86, p = 0.02). The results were consistent in multivariable analyses. The association between high FAP expression and poor outcome in high density CD8 HGSC was also confirmed in publicly available datasets. CONCLUSIONS: The TME infiltration of FAP-positive fibroblasts is associated with poor prognosis in HGSC with high CD8+ cells density. Targeting the FAP+ subset of fibroblasts may unlock the local immune-activation in the TME thus enhance the positive prognostic effect of T-cells in ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Corvigno S, Fernebro J, Karlsson JS, et al. High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density. Gynecol Oncol. 2025. PMID: 39914230. doi:10.1016/j.ygyno.2025.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。